Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Press Micronesia.
Press releases published on September 8, 2025
Prenetics’ IM8 Congratulates Global Ambassador and Shareholder - World No. 1 Aryna Sabalenka on Defending Her US Open Championship
GlobeNewswire
·
September 8, 2025
Aryna Sabalenka becomes first woman to defend US Open title in more than a decade AI-powered Aryna Sabalenka ad goes viral with 233M Instagram views and Times Square billboard during US Open IM8 achieves 300,000+ customer purchases and 6 million servings …
Erste Zwischenergebnisse aus BioNTechs und BMS‘ globaler Phase-2-Studie mit bispezifischem PD-L1xVEGF-A-Antikörperkandidat Pumitamig (BNT327/BMS986545) zeigen ermutigende Anti-Tumor-Aktivität bei fortgeschrittenem kleinzelligem Lungenkrebs
GlobeNewswire
·
September 8, 2025
Daten zur Kombination des bispezifischen PD-L1xVEGF-A-Antikörper-Kandidaten Pumitamig (BNT327/BMS986545) mit Chemotherapie zeigen weiterhin ermutigende Anti-Tumor-Aktivitäten bei Patientinnen und Patienten mit kleinzelligem Lungenkrebs im fortgeschrittenen …
First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity
GlobeNewswire
·
September 8, 2025
PD-L1xVEGF-A bispecific antibody pumitamig (BNT327/BMS986545) plus chemotherapy continues to show encouraging antitumor activity in patients with extensive-stage small cell lung cancer (”ES-SCLC”), expanding evidence for its potential to set a new standard …
PsyCan Discovers Sharp Decline in Health Canada Approvals for Doctors Seeking Legal Psychedelic Therapy for Patients
GlobeNewswire
·
September 8, 2025
TORONTO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- PsyCan, the trade association representing Canada’s medical psychedelics industry, is calling for urgent reforms to the way Canadians access psychedelics for medical purposes following a release of Health Canada …
Streamex Exchange Corp NASDAQ-BSGM Creates a Tokenized Yield-Bearing Gold Product Generating up-to 4% through Exclusive Partnership with Monetary Metals
GlobeNewswire
·
September 8, 2025
Partnership unlocks exclusive tokenization rights, a four percent (4%) annual yield target on physical bullion, revenue share tied to leasing volumes and the creation of a groundbreaking institutionalized asset providing yield on physical gold holdings Key …
Novatio Solutions Strengthens European Presence with New Office in Germany
GlobeNewswire
·
September 8, 2025
MANNHEIM, Germany, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Novatio Solutions, a niche consulting and implementation partner specializing in Supply Chain Transformation and AI, has officially expanded its global footprint with the opening of its new office in …
BlueGenesLab Expands Genetic Panel to Include Three New GLP-1–Related Genes
GlobeNewswire
·
September 8, 2025
SCOTTSDALE, Ariz., Sept. 08, 2025 (GLOBE NEWSWIRE) -- BlueGenesLab, a precision genomics company headquartered in Scottsdale, Arizona, today announced the addition of three genes to its clinical testing panel that influence GLP‑1 (glucagon‑like peptide‑1) …
Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform
GlobeNewswire
·
September 8, 2025
WARREN, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today shared the risk-adjusted net present value (rNPV) estimate of $9 billion to $11 billion for TVGN-489, an allogeneic precision T cell …
New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEM
GlobeNewswire
·
September 8, 2025
PRINCETON, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the presentation of new 4-year muscle function, muscle strength and biomarker endpoints from the PROPEL open-label extension (OLE) study of …
Journal of Healthcare Management Study Uncovers Critical Gaps in Hospital Employee Surveys Used to Assess Risk of Clinician Turnover, Unveiling Need for Atalan Platform
GlobeNewswire
·
September 8, 2025
Data found 12 times higher risk of turnover among nonresponding clinicians, revealing how nonresponse bias distorts survey results and emphasizing the need for objective data solutions Study co-authored by world-renowned labor economist and Harvard …
Femasys Secures Regulatory Approval for FemBloc® Permanent Birth Control in New Zealand
GlobeNewswire
·
September 8, 2025
ATLANTA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced it has received approval from …
New Omada Health Analysis Shows Long-Term Weight Maintenance Post-GLP-1 Discontinuation, Challenging Industry Assumptions
GlobeNewswire
·
September 8, 2025
SAN FRANCISCO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, released results from a real-world analysis that showed 63% of Omada members maintained or continued to lose weight 12 months …
Queen Latifah Named Spokeswoman as WeightWatchers Launches First Comprehensive Menopause Program
GlobeNewswire
·
September 8, 2025
NEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“WeightWatchers” or the “Company”), the global leader in science-backed weight management, today announced the launch of WeightWatchers for Menopause, a groundbreaking …
Lifeward Achieves CE Mark Approval for the ReWalk 7 Personal Exoskeleton
GlobeNewswire
·
September 8, 2025
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or …
Cannabix Technologies to Exhibit at National Safety Council (NSC) Safety Congress and Expo, Denver Colorado
GlobeNewswire
·
September 8, 2025
VANCOUVER, British Columbia, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) developer of marijuana and alcohol breath testing devices is pleased to report its …
Dentsply Sirona Retains Wellspect Healthcare as a Portfolio Business Following Comprehensive Review of Strategic Alternatives
GlobeNewswire
·
September 8, 2025
CHARLOTTE, N.C., Sept. 08, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company has completed the evaluation of strategic alternatives for its Wellspect Healthcare business (“ …
Pelthos Therapeutics to Participate in Upcoming September Investor Conferences
GlobeNewswire
·
September 8, 2025
DURHAM, N.C., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company (“Pelthos” or the “Company”) committed to commercializing innovative therapeutic products for high unmet patient needs, today …
CorMedix Announces Strategic Minority Investment in Talphera
GlobeNewswire
·
September 8, 2025
BERKELEY HEIGHTS, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced …
Vivos Inc. Demonstrates Precision in Precision Radionuclide Therapy
GlobeNewswire
·
September 8, 2025
Kennewick, WA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) announced new data demonstrating the exceptional precision of its proprietary Precision Radionuclide Therapy (RadioGel® for human therapies and IsoPet® for veterinary applications) …
I-Mab Announces Acceleration of Givastomig Investment and Leadership Appointments
GlobeNewswire
·
September 8, 2025
Expands investment in givastomig in 1L metastatic gastric cancers, with plans to initiate a global randomized Phase 2 study in combination with immunochemotherapy, in Q1 2026, with additional Phase 1b cohorts to follow Reiterates expectations to report …